Jefferies Tells Investors to Rotate to Dividend Heavyweights as AI Hype Cools

Jefferies Sounds Alarm on AI, Steers Investors to Income Stocks

Jefferies is urging investors to shift away from the hyped-up artificial intelligence rally and toward defensive, high-yield U.S. equities. In a note earlier this month, strategist Desh Peramunetilleke warned that rising uncertainty over the payoff from hyperscalers' massive spending on data centers and chips could spark a painful reset in AI-related shares.

Instead, his team screened for companies with a market value above $10 billion that land in the bottom fifth of share-price volatility and offer a forward dividend yield or free-cash-flow yield above 3%. Crucially, they also required that 2026 earnings estimates have not declined over the past three months, signaling stable financial health.

The screen surfaced four names: consumer goods giant Procter & Gamble, pharmaceutical heavyweight Pfizer, regional bank KeyCorp, and mall operator Simon Property Group. Each has lagged the broader market this year but, in Jefferies' view, provides a rare combination of income and resilience at a time when AI's fortunes look increasingly fragile.

The Screen That Singled Out PG, Pfizer, KeyCorp, and Simon

Why Jefferies Is Ringing the Alarm on AI

The strategist's call comes as skepticism grows over the massive capital outlays by hyperscale cloud providers on AI infrastructure. While the technology's long-term potential remains intact, the near-term return on those billions of dollars is increasingly contested by analysts and investors alike. A retreat from AI momentum plays could unwind the gains concentrated in a narrow group of chip and platform stocks, creating a powerful rotation toward steadier, income-generating alternatives.

A Closer Look at the Four Survivors

Procter & Gamble offers a forward dividend yield around 3% and has climbed only about 3% year-to-date, trailing the broader market. Yet it delivered better-than-expected adjusted earnings and revenue in April, and product volumes grew for the first time in a year—a sign that the consumer staples titan is regaining pricing power. Its next quarterly report lands on Wednesday.

Pfizer carries a hefty forward yield of almost 7%, even though the stock is down roughly 2% in 2026. It beat consensus estimates on both profit and sales in May, and second-quarter results are due on August 4. The appeal is clear: if AI wobbles, a yield this high looks like an anchor in stormy markets, provided the drugmaker's pipeline delivers.

KeyCorp sported a dividend yield near 4% at the time of the Jefferies screen and was already up about 12% year-to-date. The regional bank has since tacked on more gains after posting second-quarter earnings per share of $0.44, about 5% ahead of the consensus $0.42, on revenue that grew almost 7% from a year earlier. Rising net interest income in a still-elevated rate environment is giving it an extra cushion.

Simon Property Group rounds out the list. As a real estate investment trust, it is a classic defensive play—high yield, low volatility, and income anchored by long-term retail leases. While the article did not detail its metrics, the stock fits the screen's income-stability profile and aligns with the broader pivot toward assets that pay investors to wait.

Winners and Losers in the Rotation

If the AI reset gathers force, the immediate losers would be the high-momentum stocks that have dominated markets since 2023—think NVIDIA, AMD, and the hyperscale cloud operators themselves. The winners, conversely, are the kinds of names Jefferies highlights: large-cap, slow-moving cash generators whose dividends are backed by real earnings, not by speculative growth narratives. But the call hinges on the assumption that AI spending truly disappoints; should hyperscalers deliver on their promised AI-driven revenue boosts, the defensive pivot may prove premature.

How to Position for the Dividend Rotation

• Mark your calendar for PG and Pfizer earnings. Procter & Gamble reports on Wednesday, giving investors a chance to verify whether volume recovery is continuing. Pfizer follows on August 4—watch for any pipeline updates that could threaten or support its nearly 7% yield.
• Use the Jefferies screen as a benchmark, not a buy list. If you share the concern about AI capex sustainability, scan your own holdings for stocks meeting similar low-volatility, 3%+ yield, and stable earnings estimate criteria. The screen is a framework, not a guarantee.
• Mind the rate backdrop for dividend plays. Both KeyCorp and other financial high-yielders are sensitive to interest-rate expectations. If the Federal Reserve signals cuts later in 2026, regional bank margins could compress, and the appeal of dividend stocks relative to bonds would shift.
• Balance a defensive tilt with early AI hedge. Rather than dumping all AI exposure, consider limiting it to a size you can hold through volatility while funding a dedicated income sleeve based on this screen's logic. The goal is not to call the exact top but to ensure your portfolio isn't wholly dependent on the AI trade.